<p>Antimicrobial resistance is a constant threat to global public health, requiring innovative strategies for therapeutic target identification. Hence, this narrative review discusses the application of structural modeling and artificial intelligence in the functional prediction of proteins encoded by multidrug-resistant bacterial genomes. Tools such as AlphaFold and RoseTTAFold have enabled high-accuracy three-dimensional structure prediction, facilitating the annotation of hypothetical proteins and the identification of conserved domains and catalytic sites. These computational approaches bridge the gap between genomic data and biological function, accelerating drug discovery and guiding design of new antimicrobial bioactive compounds. Despite notable advances, several challenges have persisted regarding experimental validation and genomic variability, revealing an opportunity to integrate artificial intelligence-driven modeling with bioinformatics as a transformative method for better understanding resistance mechanisms and prioritizing novel therapeutic targets.</p> Graphical abstract <p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Innovative approaches to therapeutic target discovery amid the global challenge of antimicrobial resistance

  • Thayssa de Oliveira Teixeira,
  • Ruana Carolina Cabral da Silva,
  • Maria Cidinaria Silva Alves,
  • Rousilândia de Araujo Silva,
  • José Eduardo Souza Echeverria,
  • Simone Simionatto

摘要

Antimicrobial resistance is a constant threat to global public health, requiring innovative strategies for therapeutic target identification. Hence, this narrative review discusses the application of structural modeling and artificial intelligence in the functional prediction of proteins encoded by multidrug-resistant bacterial genomes. Tools such as AlphaFold and RoseTTAFold have enabled high-accuracy three-dimensional structure prediction, facilitating the annotation of hypothetical proteins and the identification of conserved domains and catalytic sites. These computational approaches bridge the gap between genomic data and biological function, accelerating drug discovery and guiding design of new antimicrobial bioactive compounds. Despite notable advances, several challenges have persisted regarding experimental validation and genomic variability, revealing an opportunity to integrate artificial intelligence-driven modeling with bioinformatics as a transformative method for better understanding resistance mechanisms and prioritizing novel therapeutic targets.

Graphical abstract